No connection

Search Results

KYNB

BEARISH
$7.17 Live
Kyntra Bio, Inc. · NASDAQ
Target $43.0 (+499.7%)
$4.85 52W Range $12.6

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 13, 2026
Market cap
$29.02M
P/E
N/A
ROE
N/A
Profit margin
2848.6%
Debt/Equity
4.37
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Key Strengths

Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Occasional earnings beats on very low expectations
Low market cap provides high volatility potential for speculative traders

Key Risks

Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)
High leverage with a Debt/Equity ratio of 4.37
Deeply negative operating margins (-1058.65%)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
8
Weak
Value
5
Future
15
Past
10
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Negative Book Value, Piotroski F-Score 1/9, Revenue Collapse, Extreme Long-term Price Decay
Confidence
90%
Value
5/100

Graham Number and Intrinsic Value are unavailable due to negative earnings and equity.

Positives
No standout positives identified.
Watchpoints
  • Negative P/B ratio
  • P/S ratio of 4.51 is high for a company with shrinking revenue
Future
15/100

Growth metrics are overwhelmingly negative.

Positives
  • High analyst target price ($43)
Watchpoints
  • Revenue growth -59.30%
  • Negative EPS growth trends
Past
10/100

Long-term historical performance is catastrophic.

Positives
  • 1-year return +10.3%
Watchpoints
  • 5-year return -98.6%
  • 3-year return -98.5%
Health
10/100

Piotroski score indicates extreme weakness; Altman Z-Score not provided but implied distress.

Positives
  • Current Ratio 3.39
Watchpoints
  • Piotroski F-Score 1/9
  • Debt/Equity 4.37
  • Negative ROA
Dividend
0/100

Non-dividend paying biotech.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$7.17
Analyst Target
$43.0
Upside/Downside
+499.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for KYNB and closest competitors.

Updated 2026-04-10
KYN
Kyntra Bio, Inc.
Primary
5Y
-98.6%
3Y
-98.5%
1Y
+10.3%
6M
-32.0%
1M
+0.7%
1W
+2.3%
BTA
BioXcel Therapeutics, Inc.
Peer
5Y
-99.8%
3Y
-99.6%
1Y
-30.1%
6M
-56.4%
1M
-37.0%
1W
-18.7%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
EKS
Ekso Bionics Holdings, Inc.
Peer
5Y
-91.1%
3Y
-64.0%
1Y
+54.0%
6M
+66.6%
1M
-27.2%
1W
-18.0%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.7
PEG Ratio
N/A
P/B Ratio
-0.97
P/S Ratio
4.51
EV/Revenue
-0.91
EV/EBITDA
0.13
Market Cap
$29.02M

Profitability

Profit margins and return metrics

Profit Margin 2848.63%
Operating Margin -1058.65%
Gross Margin -273.8%
ROE N/A
ROA -16.96%

Growth

Revenue and earnings growth rates

Revenue Growth -59.3%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
4.37
High debt
Current Ratio
3.39
Strong
Quick Ratio
3.19
Excellent
Cash/Share
$21.99

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
78.2%
Op. Margin
-1058.7%
Net Margin
-1113.5%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$-0.0B
Debt/Equity
-3.83x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-11
$N/A
2026-03-16
$-3.51
+9.7% surprise
2025-11-10
$49.61
+1338.7% surprise
2025-08-11
$-1.88
-288.0% surprise

Healthcare Sector Comparison

Comparing KYNB against 291 companies in the Healthcare sector (20 bullish, 99 neutral, 172 bearish)
Profit Margin
2848.63%
This Stock
vs
-9.43%
Sector Avg
-30296.2% (Weaker)
Debt to Equity
4.37
This Stock
vs
3.74
Sector Avg
+16.8% (Higher)
Revenue Growth
-59.3%
This Stock
vs
80.78%
Sector Avg
-173.4% (Slower)
Current Ratio
3.39
This Stock
vs
3.72
Sector Avg
-8.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

WETTIG THANE
Chief Executive Officer
Buy
2025-11-17
3,700 shares · $33,750
Insider transactions can signal confidence or concerns about company prospects

Past News Coverage

Recent headlines mentioning KYNB from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile